Clinical Trial Update: Optimal Dose of Irbesartan for Renoprotection in Type 2 Diabetic Patients With Persistent Microalbuminuria [Phase 4]

View source ↗

Summary

A Phase 4 trial completed evaluating the optimal dose of irbesartan for renoprotection in adults with type 2 diabetes mellitus and persistent microalbuminuria.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Nephropathy
• Type 2 Diabetes Mellitus

Drugs mentioned

• AVAPRO (irbesartan)

Snippet

Sponsor: Steno Diabetes Center Copenhagen | Conditions: Type 2 Diabetes, Microalbuminuria | Phase 4 | Status: COMPLETED